Journal: Molecules

Article Title: The Main Structural Unit Elucidation and Immunomodulatory Activity In Vitro of a Selenium-Enriched Polysaccharide Produced by Pleurotus ostreatus

doi: 10.3390/molecules27082591

Figure Lengend Snippet: Effects of Se-POP-21 on the expression of CD80 ( a ) and CD86 ( b ) in RAW264.7 cells, as measured by flow cytometry. The data are expressed as mean ± SD; ** p < 0.01 compared with the control group.

Article Snippet: CD80 and CD86 antibodies (FITC) were purchased from Sino Biological Inc. (Beijing, China).

Techniques: Expressing, Flow Cytometry

Journal: EBioMedicine

Article Title: Inhibition of oncogenic Src induces FABP4-mediated lipolysis via PPARγ activation exerting cancer growth suppression

doi: 10.1016/j.ebiom.2019.02.015

Figure Lengend Snippet: Src regulation of tumor growth and lipid droplet is FABP4-dependent in vitro and in vivo . (a) Lipid staining (left) and quantification (right) in HBEC-C1-PPARγ (upper) and Calu6 (lower) cells. Cells were treated with 5 μM of SU6656 (SU), 20 μM of HTS01037 (HTS) or both for 3 days. (b) In vitro cell growth assay upon Src inhibitor treatment. Cell proliferation (left) and MTT (right) assays showed inhibition of cell proliferation upon SU6656 treatment for 7 days in Calu6. (c-d) In vivo analysis of the xenograft tumors by inhibiting oncogenic Src. Five millions of Calu6 cells were injected into the flank region of athymic nude mice. When tumors were tangible, mice were intraperitoneally administered with vehicle ( n = 5) or SU6656 20 mg/kg ( n = 7) for 23 days every other day. (c) Tumor growth suppression upon SU6656 treatment. Both tumor volume (left) and tumor weight (right) were measured every other day or at the end of the experiment, respectively. Tumor growth were represented as mean relative tumor size ± SEM. Statistical analysis was determined using 2-way ANOVA. (d) Intratumoral lipid amount and FABP4 protein expression. Intratumoral lipid content (upper) or FABP4 expression (lower) were assayed in the residual tumor tissues at the end of in vivo experiment. Note that a pair of representative figures was shown for lipid staining. Values are mean ± SEM. Statistical significance was assessed using Student's t -test. Asterisks refer to * P ≤ 0∙05; ** P ≤ 0∙01; *** P ≤ 0∙001; **** P ≤ 0∙0001 (One-way ANOVA, Tukey's post test (a), Student's t -test (b, c (right) and d) and two-way ANOVA, Sidak's post test (c (left))).

Article Snippet: Purchased are various chemicals including pioglitazone (Cat# sc-204848) from Santa Cruz, SU6656 (Cat# sc-203286A) from Santa Cruz or SU6656 (Cat# S7774) from Selleckchem, PP2 (Cat# 1767-1) from BioVision, HTS01037 (Cat# 10699-10) from Cayman Chemical and Stattic (Cat# S7947), Thiazolyl Blue Tetrazolium Blue (Cat# M2128) or Oil-red O (Cat# O1391) from Sigma-Aldrich.

Techniques: In Vitro, In Vivo, Staining, Growth Assay, Inhibition, Injection, Expressing

Journal: EBioMedicine

Article Title: Inhibition of oncogenic Src induces FABP4-mediated lipolysis via PPARγ activation exerting cancer growth suppression

doi: 10.1016/j.ebiom.2019.02.015

Figure Lengend Snippet: Intracellular ROS generation upon lipolysis regulation. (a) Measurement of intracellular ROS. Cells were treated with 5 μM of SU6656 (SU) in the presence or absence of 20 μM of FABP4 inhibitor HTS01037 (HTS) for 3 days and followed by incubation with 1 μM of CM-H 2 DCF-DA for H1993 or 2∙5 μM of CM-H 2 DCF-DA for Calu6 cells. Pictures were taken using confocal microscope followed by quantitative analysis using MetaMorph 6.3 software (Molecular Devices). Scale bar = 20 μm (b) AMPK phosphorylation upon inhibitor treatment. Cells treated with SU or HTS for 3 days were assayed for AMPK and pAMPK expression in H1993 and Calu6 cells. (c) Oxygen consumption rates in lung cancer cell lines with inhibitor treatment. Calu6 and H1993 cells were treated with SU, HTS or both for 3 days. The OCRs were measured as in materials and methods. (d) Cell growth assay with inhibitor treatment. Cell proliferation and MTT assays show cell viability under SU, HTS, or both treatment for 3 days. (e) Protein expression involved in regulation of cell cycle or apoptosis in Calu6 and H1993 upon indicated treatment for 24 h. Values are mean ± SEM. Results represent data from at least two independent experiments. Asterisks refer to * P ≤ 0∙05; ** P ≤ 0∙01; **** P ≤ 0∙0001 (One-way ANOVA, Tukey's post test).

Article Snippet: Purchased are various chemicals including pioglitazone (Cat# sc-204848) from Santa Cruz, SU6656 (Cat# sc-203286A) from Santa Cruz or SU6656 (Cat# S7774) from Selleckchem, PP2 (Cat# 1767-1) from BioVision, HTS01037 (Cat# 10699-10) from Cayman Chemical and Stattic (Cat# S7947), Thiazolyl Blue Tetrazolium Blue (Cat# M2128) or Oil-red O (Cat# O1391) from Sigma-Aldrich.

Techniques: Incubation, Microscopy, Software, Phospho-proteomics, Expressing, Growth Assay